At A Glance:

With this Phase III, 2-protocol program, the sponsor hoped to extend the label of its antidepressant drug to children and adolescents.

Download PDF
Indication:

Pediatric Depression

Enrollment time saved (protocol 1): 56 months
Enrollment time saved (protocol 2): 76months
See the results
Case Study

AES Shortens Timelines by up to 20 Months for a Uterine Fibroid Program

VIEW CASE STUDY >
Case Study

AES Helped to Put a Sponsor at the Forefront of a Chronic Disease Market

VIEW CASE STUDY >
Case Study

Thanks to AES, a Sponsor Won its Race to Market with a New Class of OIC Drug

VIEW CASE STUDY >
Case Study

AES Shortens Enrollment by 7 Months for a Crucial Migraine Phase IIb Study

VIEW CASE STUDY >
Case Study

AES Saves More than 4 Months of Enrollment Time and $2.2 Million for Phase III Atopic Dermatitis Study

VIEW CASE STUDY >